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Introduction
While the teratogenic activities of cannabis have been 
investigated since the 1960s,1,2 substantially higher lev-
els of Δ9-tetrahydrocannabinol of currently used canna-
bis3 suggests that the neonatal epidemiology of former 
years requires reexamination.4,5
Urgency for epidemiological reassessment achieves 
particular currency in view of recent US data indicating 
that 24% of pregnant Californian teenagers test positive 
for cannabinoids,6 that 69% of pregnant Coloradan 
mothers have cannabis recommended to them by can-
nabis dispensaries,7 and that 161 000 pregnant women 
across the United States admitted to cannabis use during 
their pregnancy.8
In such a context, experience from flagship states 
such as Colorado, which has been a pioneer in US can-
nabis use and also supports a detailed and public data-
base of congenital defects, is invaluable to ascertain 
current trends and likely future directions. Cannabis was 
permitted for medicinal use from November 2000 and 
was decreed legal in November 2011 with full effect 
from 2014.
Colorado also has one other considerable advantage 
that greatly simplifies the statistical analysis of its data, 
as during the period 2000 to 2014, nationally representa-
tive datasets indicate that the use of other drugs was 
static or falling. In this sense, therefore, the Coloradan 
context is ideal from a statistical and public health per-
spective to ascertain current teratological trends while 
statistically isolating the effect of rising cannabinoid 
exposure to facilitate the study of prenatal cannabis 
exposure (PCE).
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Abstract
Rising Δ9-tetrahydrocannabinol concentrations in modern cannabis invites investigation of the teratological 
implications of prenatal cannabis exposure. Data from Colorado Responds to Children with Special Needs (CRCSN), 
National Survey of Drug Use and Health, and Drug Enforcement Agency was analyzed. Seven, 40, and 2 defects were 
rising, flat, and falling, respectively, and 10/12 summary indices rose. Atrial septal defect, spina bifida, microcephalus, 
Down’s syndrome, ventricular septal defect, and patent ductus arteriosus rose, and along with central nervous 
system, cardiovascular, genitourinary, respiratory, chromosomal, and musculoskeletal defects rose 5 to 37 times 
faster than the birth rate (3.3%) to generate an excess of 11 753 (22%) major anomalies. Cannabis was the only drug 
whose use grew from 2000 to 2014 while pain relievers, cocaine, alcohol, and tobacco did not. The correlation of 
cannabis use with major defects in 2014 (2019 dataset) was R = .77, P = .0011. Multiple cannabinoids were linked 
with summary measures of congenital anomalies and were robust to multivariate adjustment.
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delta9-tetrahydrocannabininol, cannabidiol, epigenetic genotoxicity, congenital teratogenicity, congenital 
cardiovascular malformations
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This study explores the presence of any overall trends 
in the pattern of Coloradan congenital anomalies data and 
investigates the extent to which ecologically documented 
drug use trends explained some of this variance.
Methods
Data
Data on birth defects in Colorado were taken from the 
Colorado Responds to Children with Special Needs 
(CRCSN) online database as single data points in 
January 2019.9 Total 2013 defect data were taken from 
the April 2018 CRCSN dataset. Data on drug use were 
taken from the National Survey of Drug Use and Health 
(NSDUH) conducted annually by the Substance Abuse 
and Mental Health Administration (SAMHSA).8 Data 
on cannabinoid concentration were taken from the 
National Drug Enforcement Agency seizures10,11 and 
multiplied by annual cannabis use to derive state-wide 
cannabinoid exposure.
Relationship to Cannabis
Defects were classified as cannabis-related if strong pub-
lished evidence had previously identified a relationship to 
cannabis exposure. Papers from Centers for Disease 
Control and Prevention (CDC) and National Birth Defects 
Prevention Network (NBDPN) have established that 
anencephaly,12,13 diaphragmatic hernia, esophageal atre-
sia with or without tracheoesophageal fistula, and gas-
troschisis are cannabis-related.12 A joint statement by the 
American Academy of Pediatrics and the American Heart 
Association linked Ebstein’s anomaly and ventricular 
septal defect (VSD) with cannabis use.14 A large 2007 
epidemiological study from Hawaii also linked encepha-
locele, hypoplastic left heart, syndactyly, reduction defor-
mity of the upper limbs, hydrocephaly, cleft lip and cleft 
palate both separately and together, anotia/microtia, 
tetralogy of Fallot, pyloric stenosis, microcephaly, pul-
monary valve atresia and/or stenosis, large bowel or rectal 
atresias or stenosis, obstructive genitourinary defect, 
polydactyly, atrial septal defect (ASD), and trisomy 21 
with PCE.15 Although this study is an outlier in terms of 
the literature, this list of defects was accepted as being 
cannabis-related in view of its high predictive value and 
pointed real-world applicability particularly in the United 
States (see Results and Discussion sections).
Statistics
Data were processed in “R” v3.5.2 and “R Studio” 
v1.1.463 from the Central “R” Archive Network. Model 
reduction was conducted by the classical method with 
progressive removal of the least significant term. Models 
were compared by analysis of variance (ANOVA). 
Model parameters were compared with the “purrr” and 
“broom” packages. Regression line slope change was 
assessed with the “segmented” package. Differing quan-
titative scales were adjusted using the “scales” package. 
The “nlme” package was used for mixed-effects regres-
sion. Principal components analysis was conducted 
using the “psych” package. P < .05 was considered 
significant.
Ethics
The study was approved by the Human Research Ethics 
Committees of South City Medical Centre and the 
University of Western Australia.
Results
The January 2019 CRCSN dataset consists of annual 
numbers and rates on 49 defects for each of the years 
2000 through 2014 and comprises 746 data points 
together with 180 data points relating to 13 summary 
indices by major organ system. These defects are 
graphed by time in Figures 1 and 2.
Table 1 lists the slope and confidence intervals of 
these time-dependent changes. Seven defects are noted 
to be significantly rising and 2 significantly falling. 
Table 2 repeats this exercise for the major defect sum-
mary groups. Nine of 11 slopes are noted to be rising. 
Supplementary Figures 1 and 2 (available online) pres-
ent loess curves for these data.
Since the data are rather difficult to mentally digest 
en masse, Figures 3 to 8 present data grouped by organ 
system. Figure 9 illustrates the summary data by organ 
system.
Figure 10 shows the numbers of defects as a total 
number and as a percentage of live born babies. The 
total figure in the April 2018 CRCSN dataset is noted to 
be substantially higher than that in the January 2019 
CRCSN dataset. Figure 11 shows the relative rise from 
baseline of the various categories with the origin of each 
dataset forming the baseline comparator for that group.
Supplementary Table 1 (available online) shows the 
summaries of regression models for these major defects 
and defect classes. Table 3 lists the number of cases in 
each group by year, sums the total, compares it with the 
calculated total based on 15 times (2000:2014) the low-
est rate in either 2000 or 2001, calculates the absolute 
and relative case excess, and compares it with the rise in 
births from 2000 to 2014 of 3.3069%. These relative 
case excesses are then graphed in order in Figure 12.
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Table 1. Time-Dependent Trends of CRCSN Defects.
Defect Term β-Estimate Standard Error t P Lower CI Upper CI
Atrial septal defect secundum Year 6.4518 0.7943 8.1229 .0000 4.7359 8.1677
Ventricular septal defect Year 1.1825 0.1623 7.2866 .0000 0.8319 1.5331
Patent ductus arteriosus Year 0.9925 0.2382 4.1660 .0011 0.4778 1.5072
Chromosomal anomalies Year 0.6543 0.1545 4.2357 .0010 0.3206 0.9880
Anomalies pulmonary artery Year 0.4621 0.3210 1.4396 .1736 −0.2314 1.1556
Microcephalus Year 0.3046 0.0812 3.7519 .0024 0.1292 0.4801
Trisomy 21 Year 0.1850 0.0673 2.7480 .0166 0.0396 0.3304
Renal agenesis Year 0.0961 0.0394 2.4378 .0299 0.0109 0.1812
Total anencephalus and spina bifida Year 0.0843 0.0467 1.8052 .0942 −0.0166 0.1852
Hirschsprung’s Year 0.0754 0.0457 1.6485 .1232 −0.0234 0.1741
Spina bifida without anencephalus Year 0.0693 0.0405 1.7094 .1111 −0.0183 0.1568
Anomalies abdominal wall Year 0.0507 0.0528 0.9610 .3541 −0.0633 0.1647
Choanal atresia Year 0.0489 0.0405 1.2086 .2483 −0.0385 0.1364
Microphthalmos Year 0.0296 0.0305 0.9723 .3486 −0.0362 0.0955
Endocardial cushion defects Year 0.0221 0.0434 0.5106 .6182 −0.0716 0.1158
Anencephalus Year 0.0154 0.0224 0.6847 .5056 −0.0331 0.0638
Trisomy 18 Year 0.0150 0.0267 0.5619 .5838 −0.0427 0.0727
Anophthalmos Year 0.0139 0.0218 0.6402 .5332 −0.0331 0.0609
Encephalocele Year 0.0129 0.0110 1.1654 .2648 −0.0110 0.0367
Transposition great vessels Year 0.0107 0.0540 0.1983 .8458 −0.1060 0.1274
Congenital biliary atresia Year 0.0096 0.0273 0.3538 .7291 −0.0492 0.0685
Exstrophy urinary bladder Year 0.0072 0.0166 0.4304 .6770 −0.0305 0.0448
Common ventricle Year 0.0064 0.0284 0.2266 .8242 −0.0548 0.0677
Coarctation aorta Year 0.0032 0.0768 0.0418 .9673 −0.1628 0.1692
Congenital scoliosis Year 0.0029 0.0234 0.1222 .9046 −0.0477 0.0534
Polydactyly syndactyly Year −0.0014 0.1724 −0.0083 .9935 −0.3738 0.3710
Leg reduction Year −0.0018 0.0324 −0.0551 .9569 −0.0717 0.0682
Congenital buphthalmos Year −0.0032 0.0157 −0.2043 .8413 −0.0372 0.0308
Common truncus Year −0.0032 0.0267 −0.1205 .9059 −0.0608 0.0544
Orofacial anomalies Year −0.0046 0.0921 −0.0504 .9606 −0.2036 0.1943
Hypoplastic left heart Year −0.0096 0.0367 −0.2631 .7966 −0.0888 0.0695
Cleft Lip with/without cleft palate Year −0.0114 0.0828 −0.1381 .8923 −0.1903 0.1674
Limb reduction Year −0.0125 0.0330 −0.3785 .7112 −0.0838 0.0588
Trisomy 13 Year −0.0125 0.0235 −0.5311 .6043 −0.0633 0.0383
Tracheoesophageal fistula esophageal 
atresia stenosis
Year −0.0146 0.0475 −0.3086 .7625 −0.1172 0.0879
Anomalies diaphragm Year −0.0146 0.0543 −0.2697 .7917 −0.1320 0.1027
Total anomalous pulmonary venous 
connection
Year −0.0204 0.0262 −0.7768 .4512 −0.0770 0.0363
Cleft palate without cleft lip Year −0.0214 0.0916 −0.2340 .8186 −0.2193 0.1764
Atresia stenosis bladder neck Year −0.0304 0.0391 −0.7759 .4517 −0.1149 0.0542
Congenital hydrocephalus without 
spina bifida
Year −0.0318 0.0584 −0.5443 .5954 −0.1579 0.0944
Tetralogy Fallot Year −0.0389 0.0524 −0.7425 .4710 −0.1522 0.0743
Arm reduction Year −0.0414 0.0381 −1.0881 .2963 −0.1237 0.0408
Cong stenosis aortic valve Year −0.0568 0.0337 −1.6866 .1155 −0.1295 0.0160
Hip dysplasia Year −0.0639 0.1674 −0.3819 .7087 −0.4256 0.2977
Congenital cataract Year −0.0689 0.0346 −1.9903 .0680 −0.1437 0.0059
Atresia stenosis large intestine Year −0.0936 0.0641 −1.4594 .1682 −0.2321 0.0449
Infantile cerebral palsy Year −0.1325 0.0730 −1.8158 .0925 −0.2901 0.0251
Pyloric stenosis Year −0.2529 0.1057 −2.3912 .0326 −0.4813 −0.0244
Pulmonary valve stenosis atresia Year −0.3271 0.1009 −3.2417 .0064 −0.5452 −0.1091
Abbreviations: CRCSN, Colorado Responds to Children with Special Needs; CI, confidence interval.
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En passant one notes that the rate of rise of the 2 com-
mon cardiac defects ASD (secundum type) and patent 
ductus arteriosus (PDA) appears to rise sigmoidally 
across this time period of the cannabis legalization pro-
cess (Figure 13). One notes that the quartic model 
accounts for the time-dependent variance significantly 
better than the linear model for both ASD (ANOVA F = 
6.6319, degrees of freedom [df] = 3, P = .0096) and 
PDA (ANOVA F = 5.413, df = 3, P = .018).
Since both the American Academy of Pediatrics and 
the American College of Obstetricians and Gynecologists 
concur that drug use in the peripartum period is harmful 
to the fetus,16,17 it is reasonable to consider the potential 
role of drug use by the parents in a possible epidemiologi-
cal association with this overall increasing defect profile.
Drug use in Colorado is presented from the SAMHSA 
NSDUH data as least squares regression lines in Figure 
14, and the slopes of these lines are summarized in Table 
4. Only the slopes of the cannabis curves are seen to be 
rising; the slopes of the tobacco, cigarette, cocaine, and 
pain reliever curves are falling significantly.
Figure 15 presents these drug use data with loess 
curves. Formal testing for change of regression slope for 
monthly cannabis use showed a significant change in 
2007 from .0293 to .11917 (Davies test, k = 3, P = 
.0002).
Monthly cannabinoid exposure was calculated by 
multiplying the concentration of Federal cannabis sei-
zures by within-state monthly cannabis use. These data 
are presented as regression lines and loess curves in 
Figures 16 and 17.
Because many of the 49 defects had different quanti-
tative rates, they were scaled to mean of 0 and standard 
deviation of 1 using the “scales” package. The time-
dependent plots shown in Figure 18 were obtained.
A similar exercise was conducted, illustrated in 
Figure 19, which charts the scaled defect rate as a linear 
temporal function of the various drug exposures. 
Increasing levels of binge alcohol, cocaine, cannabis, 
and pain relievers are all noted to be linked to higher 
rates of congenital defects. These relationships are dem-
onstrated in Table 5. One notes that the quartic model for 
cannabis has a higher F value and lower model P value 
than that for opioid pain relievers (7.83 vs 4.422 and 3.5 
× 10−7 vs 3.4 × 10−5).
Table 6 compares the defect rates against multiple 
drug exposure in additive models and increasingly com-
plex interactive mixed-effects models with defect as the 
random variable. Terms including cannabis exposure 
persisted in final models.
As described in Methods, defects were assigned to 
be either cannabis-related or not based on reports in 
the published literature. However, as the Hawaiian 
report of pyloric stenosis being cannabis-linked15 has 
not been confirmed elsewhere, this condition was 
removed from the cannabis-associated group. 
Moreover, 2 reports from CDC/NBDPN indicate that 
PCE is linked with anencephaly.12,13 Several drugs 
linked with anencephaly are similarly linked with 
spina bifida, which is accepted to be a prototypical 
neural tube closure defect so that it seems likely that 
cannabis may also be linked with spina bifida with or 
without anencephaly. Graphs showing the effect of 
these 2 adjustments are included as Supplementary 
Figures 3 to 6 (available online).
Figure 20 shows the time relationship of the 49 scaled 
defects by the above-described relationship to cannabis. 
These data are shown on single plots with both loess 
curves and linear regression lines in Figure 21.
A model quartic-in-time was superior to a linear-only 
model (ANOVA F = 4.6099, df = 5, P = .0004).
Table 7 shows that the results of both linear and quar-
tic models are significant with cannabis terms remaining 
Table 2. Time-Dependent Trends of CRCSN Major Defect Classes.
Defect Term β-Estimate Standard Error t P Lower CI Upper CI
Major Defects Number 2013 Year 228.4791 17.7906 12.8427 .000000 189.7167 267.2415
Major Defects Number 2014 Year 92.9179 11.5577 8.0395 .000002 67.9489 117.8868
Major Defects Rate 2014 Year 15.6757 2.2823 6.8684 .000011 10.7451 20.6063
Major Genitourinary Defects Year 6.1111 0.6297 9.7052 .000000 4.7508 7.4714
Major Cardiovascular Defects Year 6.0657 0.8369 7.2476 .000006 4.2576 7.8738
Major Musculoskeletal Anomalies Year 3.6582 0.5886 6.2149 .000031 2.3866 4.9298
Major Musculoskeletal Defects Year 3.6329 0.5912 6.1449 .000035 2.3556 4.9101
Respiratory Anomalies Year 1.9304 0.2758 6.9991 .000009 1.3345 2.5262
Chromosomal Anomalies Year 0.6543 0.1545 4.2360 .000973 0.3210 0.9880
Major Gastrointestinal Defects Year 0.2061 0.3224 0.6393 .533760 −0.4903 0.9025
Major Eyes Defects Year 0.0289 0.0807 0.3585 .725688 −0.1454 0.2032
Abbreviations: CRCSN, Colorado Responds to Children with Special Needs; CI, confidence interval.
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in final models both as a factor and in interaction with 
time and time-squared.
Figure 22 shows the time relationship of exposure to 
various cannabinoids with regression lines, and loess curves 
are shown in Supplementary Figure 7 (available online).
Figure 23 shows the defects charted against cannabinoid 
exposure. These relationships are formalized in Table 8.
Figure 24 illustrates the complex relationship 
between monthly cannabis use, falling cannabidiol con-
centration, and the population exposure to cannabidiol.
Figure 25 is a point and box plot graph of the move-
ment of cannabis-related versus nonrelated defects for 
each year to address the complex relationship of canna-
bidiol exposure.
Figure 3. Central nervous system (CNS) defects by time.
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Figure 26A shows these 2 rates side by side from 
2000 to 2014. The difference between the 2 groups is 
plotted in Figure 26B, and their adjusted ratio (adjusted 
by adding unity [1] to numerator and denominator) 
appears in Figure 26C. Figure 26D shows the ratio of the 
absolute values of the cannabis-related and non–canna-
bis-related values, which correlates broadly with canna-
bidiol exposure (Figure 24C, R = 0.4857, P = .0783). 
These measures clearly peaked in 2009-2010 when can-
nabidiol exposure also peaked.
Figure 9 and Table 2 showed that defects in 5 major 
organ systems are rising: central nervous system, cardio-
vascular, genitourinary, musculoskeletal, and respiratory 
systems. These 5 may then be combined by principal 
component analysis. A scree plot (Supplementary 
Figure 8, available online) shows that 1 principal 
component—PC1—was sufficient to combine these data 
and accounted for 90% of the variance. Together with 
total rates from the CRCSN dataset, this produces 3 sum-
mary statistics, the totals for 2013, 2014, and PC1.
Figure 27 charts these parameters against each other 
along with the monthly cannabis exposure. A close 
visual relationship is immediately apparent. These cor-
relations are presented formally in Table 9.
Table 10 summarizes the regression of all scaled 
defects against various drug combinations.
Table 11 is a regression summary for all scaled 
defects against various cannabinoids.
Table 12 presents final regression models of various 
key summary parameters against the indicated combina-
tions of drugs and cannabinoids in linear and/or time-
quartic models.
Figure 4. Neural tube defects by time.
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Discussion
This study portrays a detailed picture of congenital 
defects in the state of Colorado based on the latest intra-
state defect registry data from CRCSN and provides 
compelling evidence that the generally rising pattern 
both of individual defects and of systems levels sum-
mary and total measures closely parallels the rise in can-
nabis use in Colorado in the context of static or falling 
levels of other drug use.
Figure 5. Cardiovascular defects by time.
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While there is substantial heterogeneity in the trend of 
birth defects in Colorado, the overall trend of the CRCSN 
dataset is upward, a trend that closely parallels cannabis 
use during the progression of that state toward cannabis 
legalization. This is reflected in some of the most com-
mon birth defects such as ASD, PDA, VSD, and Down’s 
syndrome and also in summary measures such as central 
nervous, cardiovascular, respiratory, chromosomal, and 
genitourinary defects, the overall total defects in both 
2013 and 2014 and on principal component analysis. 
Indeed, ASD and PDA showed an uptick temporally asso-
ciated with rising cannabis use. Cannabis use showed a 
statistically significant rise about 2007 related to the 
movement toward cannabis legalization. Moreover, the 
relationship to cannabis use was robust to multivariate 
adjustment with all other drug use. Data implicated sev-
eral cannabinoids including Δ9-tetrahydrocannabinol, 
Δ8-tetrahydrocannabinol, tetrahydrocannabivarin, 
cannabinol, and cannabidiol. Although the relationship 
with cannabidiol is temporally complex, data show that 
the relative elevation of cannabis-related defects com-
pared with non–cannabis-related defects peaked in 2009 
to 2010 when cannabidiol exposure was peaking.
It should be underscored again that the reported 
changes are all at the associational level only: such a 
study cannot by itself establish or interrogate causal 
pathways.
Moreover, as has been described elsewhere, numerous 
published mechanistic reports link PCE with molecular 
pathways to teratogenesis and form a critical backdrop 
and highly pertinent context to the present report.18-23 This 
confluence of strong mechanistic links together with the 
present compelling teratological profile in the situation 
where the use of other drugs is uniformly static or falling 
strengthens the argument that causal pathways may be 
operating in clinical populations.
Figure 6. Chromosomal defects by time.
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Space precludes detailed consideration of possible 
teratogenic mechanisms, but these have been addressed 
elsewhere.18-23 Neurotoxic mechanisms include with-
drawal of glutamate receptors from synapses,24  
misconstruction of synapses from disruption of neurexin-
neuroligin synaptic scaffolding,25 excessive dendritic and 
spine pruning,26 mitochondrial impairment,27 stem cell 
inhibition,28 CB1R-mediated neuraxis inflammation,29 
and cytoskeletal impairment and motility disruption.30 
Cardiovascular toxic mechanisms include inflammatory 
vasculitis and CB1R signaling to CB1R-rich endovascu-
lar and endocardial tissues.31,32 Importantly, cannabis has 
been described as blocking both notch33,34 and robo-slit 
receptor-ligand35 signaling, which are important as 
both neuronal and vascular guidance cues,36 and criti-
cally involved in heart and brain morphogenesis.36 
Cannabis induces severe epigenetic disruption22,37-39 
and has long been known to stimulate micronucleus 
formation and genetic anomalies secondary to chro-
mosomal missegregation.22,40
The present work did not have access to Coloradan 
early termination of pregnancy for anomaly data. Since 
many of the defects mentioned are known to be carefully 
sought by prenatal screening programs and have high 
applicable termination rates, the present results repre-
sent underestimates and set a lower bound for effect, 
which is likely to be greatly exacerbated by incorpora-
tion of the complete dataset.
Some discussion of the attribution of cannabis asso-
ciation to the listed defects is appropriate. Many of the 
defects listed as cannabis-associated have been attrib-
uted as such based on the large population survey of 
Forrester and Merz from Hawaii in 2007.15 While this 
article is an outlier in the clinical cannabis-related tera-
togenesis literature, albeit highly concordant with previ-
ous animal studies,1,2 its very uniqueness places it in a 
Figure 7. Face defects by time.
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signal position to face the most stringent test of predic-
tive theories, namely, the test of prediction of future 
trends. By this test, the Forrester-Merz article towers 
above the remainder of the literature. It alone predicts 
the increased incidence of ASD, Downs’ syndrome, 
microcephaly, and chromosomal defects found in the 
present study. Moreover, this is the only study that 
explains the current pattern of cannabis-related defects 
such as ASD, Down’s syndrome, VSD, encephalocele, 
limb reductions, anotia, and gastroschisis across the 
high cannabis-using states of the United States41 and 
recently reported elevated rates of limb defects in France 
in hemp-fed cattle and babies.42,43 As noted above, 
pyloric stenosis was omitted from the cannabis-related 
group as it has not been independently verified by other 
studies, and spina bifida is believed to share much in 
common with other neural tube closure defects such as 
anencephalus so this has been included.
Four of 4 longitudinal studies of cortical executive 
functioning following PCE indicate serious deficits in 
cerebral associational function.44-48 Data on these defi-
cits are not included within the CRCSN dataset, which 
therefore forms an additional disease burden to that 
described above. However, one notes that there has been 
a movement in Colorado for several years to declare a 
state of medical emergency related to a rapidly acceler-
ating renaissance of autistic spectrum disorders in that 
community.49 Importantly, rapid growth of autism in 
Colorado may shortly overshadow the classical anoma-
lies described in the present report, which again suggests 
that this work describes a lower bound of cannabis 
teratogenesis.
Taken together, these various data imply that the full 
spectrum of cannabis-associated defects is potentially 
much broader than has previously been delineated. It 
may still be expanding.
Figure 8. Limb defects by time.
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A major finding of this statistical study was that mod-
els quartic in time outperformed strictly linear models. 
This suggests a feed-forward–type positive-feedback 
process.
In October 2018, the CRCSN revised their total data-
base from 2000 to 2014 without explanation in a manner 
that mainly affected the total congenital anomalies. The 
previous historical totals from 2000 to 2013 appear as 
indicated.
This study has several strengths. Colorado is unusual 
among the United States in that it makes extracts from 
its birth defects register publicly available. Colorado is 
also unusual as it is one of the only states with legal can-
nabis to do so. This study also utilizes the very large 
Figure 9. Major defects by time.
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nationally representative NSDUH dataset to assess 
intrastate drug exposure. Limitations include the lack of 
individual-level drug use data, which might be available 
to a case-control study. Due to the uncertainties involved 
with self-report studies,6 we would suggest that future 
studies employ objective evidence of drug exposure 
such as hair analysis.50
Conclusion
An excess of 11 753 to 20 152 birth defects occurred in 
Colorado from 2000 to 2014, which represents a 6.7- to 
9.4-fold excess of growth in defects compared with 
growth in births. Defects in 6 of 8 major organ systems 
increased significantly in frequency. While other drug 
use was falling over this period, cannabis use alone rose. 
Cannabis and many cannabinoids were shown to be 
associationally linked with this rise with correlation 
coefficients up to 0.78, were confirmed on bivariate 
analysis, and were robust to multivariate adjustment. In 
the context of multiple mechanistic pathways, causality 
is strongly implied. Longitudinal case-control series 
denominated by an objective measures of drug use are 
indicated.
Figure 10. Total defects by time.
Reece and Hulse 1099
Figure 11. Relative rises in selected defects compared with baseline by time.
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Figure 12. Rise in selected defects relative to rise in births by time.
Figure 13. Atrial septal defect, ventricular septal defect, and patent ductus arteriosus—Loess curves by time.
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Table 4. Regression Slope Trend Estimates for Drug Use—NSDUH.
Drugs Term β-Estimate Standard Error t P Lower CI Upper CI
Cannabis—Annual Year 0.6509 0.1107 5.8808 .0001 0.4097 0.8921
Cannabis—Monthly Year 0.5822 0.0960 6.0671 .0001 0.3731 0.7913
Alcohol Monthly Year 0.1498 0.0825 1.8159 .0925 −0.0284 0.3281
Binge Alcohol Year 0.0703 0.0896 0.7842 .4481 −0.1250 0.2656
Cocaine Annual Year −0.0592 0.0260 −2.2795 .0417 −0.1158 −0.0026
Pain Relievers Year −0.0849 0.0358 −2.3698 .0419 −0.1660 −0.0039
Tobacco Monthly Year −0.2859 0.0933 −3.0651 .0098 −0.4892 −0.0827
Cigarettes Monthly Year −0.3743 0.0817 −4.5838 .0005 −0.5507 −0.1979
Abbreviations: NSDUH, National Survey of Drug Use and Health; CI, confidence interval.
Figure 14. Drug use in Colorado from National Survey of Drug Use and Health (NSDUH) dataset by time with regression 
lines fitted.
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Figure 15. Drug use in Colorado from National Survey of Drug Use and Health (NSDUH) dataset by time with loess curves 
fitted.
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Figure 16. Cannabinoid exposure in Colorado from National Survey of Drug Use and Health (NSDUH) dataset by time with 
regression lines fitted.
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Figure 17. Cannabinoid exposure in Colorado from National Survey of Drug Use and Health (NSDUH) dataset by time with 
loess curves fitted.
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Figure 18. Scaled drug use in Colorado from National Survey of Drug Use and Health dataset by time with loess curves 
fitted.
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Figure 19. Scaled drug use in Colorado from National Survey of Drug Use and Health dataset by time with regression lines 
fitted.
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Table 5. Regression Slopes for All Scaled Defects by Drug Classes.
Parameter Model
Parameter Estimate
Standard 
Error t Pr(>|t|) Adjusted R2 F df P
Linear models
Cannabis
Cannabis_Monthly −9.4175 4.3409 −2.169 0.0304 0.005634 2.932 2680 .05395
Year:Cannabis_Monthly 0.0047 0.0021 2.173 0.0301  
Opioids
Year 0.3486 0.1756 1.985 0.0477 0.009133 2.644 3532 .04856
Pain_Relevers 112.5612 62.2827 1.807 0.0713  
Year:Pain_Relevers −0.0559 0.0310 −1.804 0.0718  
Quartic models
Tobacco
(Year)^3: Tobacco 5.1567 1.7701 2.913 0.0037 0.04503 5.02 8674 4.55E-06
(Year)^3 −145.182 51.2001 −2.836 0.0047  
Alcohol
NS  
Cannabis
(Year)^2 −13.6307 3.5007 −3.894 0.00011 0.0477 7.833 5677 3.51E-07
(Year)^3 4.8938 1.5169 3.226 0.00132  
(Year)^4 −9.6683 1.6810 −5.751 1.3E-08  
Cannabis_Monthly 0.2002 0.0710 2.822 0.00492  
Opioids
Year −610.237 228.352 −2.672 0.0078 0.04869 4.422 8527 3.39E-05
(Year)^4 −309.336 103.395 −2.992 0.0029  
(Year)^2: Pain_Relevers 83.360 35.953 2.319 0.0208  
(Year)^4: Pain_Relevers 69.235 22.935 3.019 0.0027  
Cocaine
(Year)^2 32.2730 14.3249 2.253 0.0246 0.04574 5.087 8674 3.67E-06
(Year)^2: Cocaine −13.2694 5.0409 −2.632 0.0087  
Abbreviation: df, degrees of freedom.
Table 6. Regression Slopes for All Scaled Defects Against Various Drugs—Mixed-Effects Models.
Parameter
Parameter Model
Value Standard Error df t P AIC BIC LogLik
Additive model
Rate~Year+Cannabis_Monthly+Opioids+Tobacco+Cocaine+BingeAlc
Opioids 0.3479 0.1560 278 2.2311 .0265 848.7998 867.4013 −419.3999
Year 0.0448 0.0214 278 2.0954 .0370  
Increasing levels of interactive models
Rate~Year*Cannabis_Monthly+Opioids+Tobacco+Cocaine+BingeAlc
Opioids 0.4003 0.1756 278 2.2796 .0234 863.8158 882.4173 −426.9079
Year:Cannabis_Monthly 0.0000 0.0000 278 2.0248 .0438  
Rate~Year*Cannabis_Monthly*Opioids+Tobacco+Cocaine+BingeAlc
Year 6.3170 1.6760 273 3.7689 .0002 861.0326 898.0704 −420.5163
Opioids 2489.7840 680.8430 273 3.6569 .0003  
Year: Opioids −1.2360 0.3390 273 −3.6495 .0003  
Cannabis_Monthly: Opioids −392.6320 114.0330 273 −3.4431 .0007  
Year: Cannabis_Monthly: Opioids 0.1950 0.0570 273 3.4470 .0007  
Cannabis_Monthly 2101.5210 617.6850 273 3.4023 .0008  
Year: Cannabis_Monthly −1.0440 0.3060 273 −3.4071 .0008  
(continued)
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Parameter
Parameter Model
Value Standard Error df t P AIC BIC LogLik
Rate~Year*Cannabis_Monthly*Tobacco+Opioids+Cocaine+BingeAlc
Year: Cannabis_Monthly −0.0030 0.0009 275 −4.0238 .0001 875.2932 904.9767 −429.6466
Cannabis_Monthly: Tobacco 0.2550 0.0637 275 4.0089 .0001  
Year 5.5130 1.4606 275 3.7741 .0002  
Tobacco 396.3240 105.2453 275 3.7657 .0002  
Year: Tobacco −0.1990 0.0527 275 −3.7677 .0002  
Rate~Year+Cannabis_Monthly*Opioids*Tobacco+Cocaine+BingeAlc
Opioids: Tobacco −0.4067 0.1071 272 −3.7971 .0002 866.9679 907.6728 −422.4839
Cannabis_Monthly: Opioids: Tobacco 0.1857 0.0530 272 3.5015 .0005  
Cannabis_Monthly: Opioids −4.4878 1.2866 272 −3.4882 .0006  
Cannabis_Monthly 18.7962 5.6135 272 3.3484 .0009  
Cannabis_Monthly: Tobacco −0.7761 0.2343 272 −3.3130 .0010  
Cocaine −1.5894 0.5995 272 −2.6510 .0085  
Opioids 6.2896 3.0387 272 2.0698 .0394  
Abbreviations: df, degrees of freedom; AIC, Akaike information criterion; BIC, Bayesian information criterion; LogLik, log likelihood.
Table 6. (continued)
Figure 20. Scaled defects rate as a function of drug use exposure with regression lines fitted in facetted plot by relationship 
to cannabis use, after omission of pyloric stenosis and inclusion of spina bifida.
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Figure 21. Scaled defects rate as a function of drug use exposure with (A) loess curves and (B) regression lines fitted.
Table 7. Comparisons of Cannabinoid Models Linear and Quartic in Time for All Scaled Defects.
Parameter Model
Parameter Estimate
Standard 
Error t Pr(>|t|) Adjusted R2 F df P
Linear models
Defect_Rate ~ Year * Cannabis_Related
Year: Cannabis_Related 0.0402 0.0108 3.712 0.0002 0.01523 4.763 3727 .002697
Cannabis_Related −98.8011 33.3927 −2.959 0.0032  
Quartic-in-time models
Defect_Rate ~ I(poly(Year, n=4)) * Cannabis_Related
(Year)^4 −4.7042 1.4591 −3.224 0.0013 0.03908 4.711 8722 1.20E-05
Year: Cannabis_Related 5.7531 1.9252 2.988 0.0029  
(Year)^2: Cannabis_Related −4.8258 1.9287 −2.502 0.0126  
Abbreviation: df, degrees of freedom.
Reece and Hulse 1111
Figure 22. Scaled defects rate as a function of cannabinoid exposure with loess curves fitted. Facetted plot by cannabinoid.
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Figure 23. Scaled defects rate as a function of cannabinoid exposure with regression lines fitted. Facetted plot by cannabinoid.
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Figure 24. (A) Monthly cannabis use by year. (B) Cannabidiol concentration by year. (C) Cannabidiol exposure by year as the 
product of (A) and (B).
Reece and Hulse 1115
Figure 25. Relationship of scaled defects by year to described relationship to cannabis consumption from the published 
literature (see Discussion).
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Figure 26. (A) Box plot of relationship of scaled defects to time by described relationship to cannabis use. (B) Difference 
between cannabis-related and non–cannabis-related rates of scaled scores. (C) Ratio of cannabis-related and non–cannabis-
related scaled scores after adjustment by adding unity (1) to both scores. (D) The ratio of the absolute value of the cannabis-
related defects to that of the absolute value of cannabis-unrelated defects.
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Table 9. Correlation Coefficients—Major Summary Indices With Cannabis Use (see Figure 27).
Group 1 Group 2 t df P R Lower CI Upper CI
Major Defects 2014 Cannabis_Monthly 4.2597 12 .0011 0.7758 0.4169 0.9255
Major Defects 2013 Cannabis_Monthly 5.1534 11 .0003 0.8409 0.5402 0.9512
PC1 Cannabis_Monthly 4.2722 12 .0011 0.7767 0.4187 0.9258
Majors Defects 2014 PC1 11.035 13 5.7E-08 0.9505 0.8542 0.9838
Abbreviations: df, degrees of freedom; CI, confidence interval.
Table 10. Linear Regression of Major Summary Indices by NSDUH Drug Exposure.
Parameter Model
Parameter Estimate
Standard 
Error T Pr(>|t|)
Adjusted 
R2 F df P
Linear models
Majors2014~Year+Tobacco*Cannabis_Monthly+Opioids+Binge_Alcohol+Cocaine
Cannabis_Monthly 1.2139 0.1678 7.234 .0002 0.8656 22.48 3,7 .0005718
Tobacco: Cannabis_Monthly 0.4423 0.1116 3.964 .0054  
Opioids 0.3683 0.1373 2.683 .0314  
Majors2014~Year*Δ9-THC+CBDM+Tobacco+Opioids
Δ9-THC 253.3969 94.7077 2.676 .0281 0.7856 19.33 2,8 .0095
Year: Δ9-THC −0.1257 0.0471 −2.668 .0284  
PC1~Year+Tobacco*Cannabis_Monthly+Opioids+Binge_Alcohol+Cocaine
Cannabis_Monthly 1.2404 0.1962 6.322 .0004 0.8221 16.4 3,7 .001508
Tobacco: Cannabis_Monthly 0.4829 0.1305 3.701 .0076  
Opioids 0.3957 0.1605 2.465 .0431  
Major_CNS~Year+Tobacco*Cannabis_Monthly+Opioids+Binge_Alcohol+Cocaine
Cannabis_Monthly 1.1631 0.2332 4.988 .0016 0.6956 8.619 3,7 .00949
Opioids 0.6071 0.1908 3.182 .0154  
Tobacco: Cannabis_Monthly 0.4133 0.1551 2.665 .0322  
Major_CVS~Year+Tobacco*Cannabis_Monthly+Opioids+Binge_Alcohol+Cocaine
Cannabis_Monthly 1.1303 0.2331 4.85 .0019 0.6951 8.599 3,7 .009549
Tobacco: Cannabis_Monthly 0.4770 0.1550 3.077 .0179  
Opioids 0.4469 0.1907 2.344 .0516  
Quartic-in-time models
PC1~I(poly(Year, n=4))*Δ9-THC+CBDM+Tobacco+Opioids
Δ9-THC 0.6793 0.1625 4.181 .0024 0.6223 17.48 1,9 .0095
Majors2014~(poly(Year, n=4))*Cannabis_Monthly+Tobacco+Opioids+Binge_Alcohol+Cocaine
(Year)^4: Cannabis_Monthly −20.4192 0.9427 −21.66 .0294 0.9982 609.9 9,1 .03141
Year: Cannabis_Monthly 302.1905 14.3060 21.12 .0301  
Cannabis_Monthly −58.0400 2.8018 −20.71 .0307  
(Year)^3: Cannabis_Monthly 99.9858 4.8684 20.54 .0310  
(Year)^2: Cannabis_Monthly −209.6725 10.3174 −20.32 .0313  
Year 340.6153 16.8783 20.18 .0315  
(Year)^2 −270.0904 13.4573 −20.07 .0317  
(Year)^3 119.3061 6.4290 18.56 .0343  
(Year)^4 −40.3087 2.4539 −16.43 .0387  
PC1~I(poly(Year, n=4))*Cannabis_Monthly+Tobacco+Opioids+Binge_Alcohol+Cocaine
Year: Cannabis_Monthly −5.7912 1.1506 −5.033 .0024 0.8062 11.4 4,6 .005744
(Year)^2: Cannabis_Monthly 5.0229 1.0371 4.843 .0029  
(Year)^3: Cannabis_Monthly 2.9675 0.8060 3.682 .0103  
(Year)^4: Cannabis_Monthly −1.6296 0.6479 −2.515 .0456  
(continued)
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Parameter Model
Parameter Estimate
Standard 
Error T Pr(>|t|)
Adjusted 
R2 F df P
Major_CNS~I(poly(Year, n=4))*Cannabis_Monthly+Tobacco+Opioids+Binge_Alcohol+Cocaine
Year: Cannabis_Monthly −5.6711 1.5086 −3.759 .0094 0.5964 4.694 4,6 .04649
(Year)^2: Cannabis_Monthly 4.2187 1.3598 3.102 .0211  
(Year)^3: Cannabis_Monthly 2.6681 1.0568 2.525 .0450  
Major_CVS~I(poly(Year, n=4))*Cannabis_Monthly+Tobacco+Opioids+Binge_Alcohol+Cocaine
Cannabis_Monthly −54.5060 3.3030 −16.5 .0385 0.997 373 9,1 .04016
Year: Cannabis_Monthly 274.4250 16.8670 16.27 .0391  
(Year)^2: Cannabis_Monthly −192.5180 12.1640 −15.827 .0402  
(Year)^4: Cannabis_Monthly −17.3420 1.1110 −15.604 .0407  
Year 309.6860 19.8990 15.562 .0409  
(Year)^3: Cannabis_Monthly 84.3810 5.7400 14.701 .0432  
(Year)^2 −228.2030 15.8660 −14.383 .0442  
(Year)^3 103.9890 7.5800 13.719 .0463  
(Year)^4 −28.4810 2.8930 −9.844 .0644  
Abbreviations: NSDUH, National Survey of Drug Use and Health; df, degrees of freedom.
Table 10. (continued)
Table 11. Linear Regression of Major Summary Indices Against Selected Cannabinoids.
Parameter Model
Parameter Estimate
Standard 
Error T Pr(>|t|)
Adusted 
R2 F df P
Quartic-in-time models
Additive models
Majors2014~poly(Year, n=4)+Δ9-THC+CBD+CBN+THCV
Δ9-THC 0.8746 0.1535 5.699 .0001 0.7077 32.48 1,12 9.9E-05
PC1~poly(Year, n=4)+Δ9-THC+CBD+CBN+THCV
Year 2.5605 0.5875 4.358 .0024 0.9582 60.67 5,8 3.8E-06
(Year)^4 −0.8531 0.2711 −3.147 .0137  
(Year)^2 −1.0638 0.4303 −2.472 .0386  
CBN 0.4179 0.1789 2.336 .0477  
Major_CVS~poly(Year, n=4)+Δ9-THC+CBD+CBN+THCV
(Year)^4 −1.5260 0.3572 −4.273 .0027 0.9149 28.97 5,8 6.4E-05
(Year)^2 −1.9670 0.5670 −3.469 .0085  
Year 2.3018 0.7741 2.974 .0178  
CBN 0.5051 0.2357 2.143 .0645  
Majors2013~poly(Year, n=4)+Δ9-THC+CBD+CBN+THCV
CBD −1.3975 0.3085 −4.530 .0062 0.9718 60.04 7,5 .0002
THCV 1.1978 0.2796 4.284 .0078  
(Year)^4 1.9973 0.4900 4.076 .0096  
(Year)^3 −2.4039 0.6190 −3.884 .0116  
(Year)^2 −3.5165 1.0913 −3.222 .0234  
CBN 0.8580 0.2758 3.111 .0265  
Year −8.0678 2.6757 −3.015 .0296  
(continued)
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Parameter Model
Parameter Estimate
Standard 
Error T Pr(>|t|)
Adusted 
R2 F df P
Interactive models
PC1~poly(Year, n=4)*Δ9-THC+CBD+CBN+THCV
Year: Δ9-THC −2.1082 0.3168 −6.655 .0006 75.94 75.94 7,6 2.0E-05
CBD −0.3900 0.0713 −5.469 .0016  
CBN 0.5980 0.1536 3.894 .0080  
THCV 0.4206 0.1444 2.914 .0268  
Majors2013~poly(Year, n=4)*LMCann+Tob+Opioids+Binge_Alcohol+Cocaine
(Year)^3 4.5310 0.9640 4.700 .0053 0.8206 11.29 4,5 .0102
Year 3.0367 0.9432 3.219 .0235  
(Year)^2 −2.9994 1.1589 −2.588 .0490  
Majors2013~poly(Year, n=4)*Δ9-THC+CBD+CBN+THCV
Δ9-THC 3.7695 0.0983 38.354 .0166 0.9999 14750.0 11,1 .0064
CBD −1.2900 0.0356 −36.203 .0176  
(Year)^4: Δ9-THC 9.4066 0.2628 35.801 .0178  
Year: Δ9-THC −31.1351 0.9101 −34.211 .0186  
(Year)^4 23.1233 0.7273 31.791 .0200  
(Year)^2 40.8303 1.3204 30.923 .0206  
(Year)^3: Δ9-THC −23.2475 0.8131 −28.59 .0223  
CBN 1.0334 0.0472 21.908 .0290  
Year −4.7978 0.3662 −13.103 .0485  
Abbreviation: df, degrees of freedom.
Table 11. (continued)
Table 12. Linear Regression of Major Defect Indices Against Drugs and Cannabinoids Together.
Parameter Model
Parameter Estimate
Standard 
Error t Pr(>|t|) Adjusted R2 F df P
Linear models
Majors2014~Year*Δ9-THC+CBDM+Tobacco+Opioids
Δ9-THC 253.3969 94.7077 2.676 .0281 0.7856 19.33 2,8 .0008648
Year:Δ9-THC −0.1257 0.0471 −2.668 .0284  
Quartic-in-time models
Majors2014~poly(Year, n=4)*Δ9-THC+CBDM+Tobacco+Opioids
(Year)^3: Δ9-THC 3.8734 1.1020 3.515 .0126 0.7258 7.619 4,6 .01561
(Year)^2: Δ9-THC −5.4212 1.5780 −3.435 .0139  
Year: Δ9-THC 4.0698 1.3505 3.013 .0236  
(Year)^4: Δ9-THC −1.7240 0.8807 −1.958 .0980  
PC1~poly(Year, n=4)*Δ9-THC+CBDM+Tobacco+Opioids
Δ9-THC 0.6793 0.1625 4.181 .0024 0.6223 17.48 1,9 .002374
Major_CNS~poly(Year, n=4)*Δ9-THC+CBDM+Tobacco+Opioids
(Year)^2: Δ9-THC −6.4699 1.7370 −3.725 .0098 0.6103 4.915 4,6 .04217
Year: Δ9-THC 4.8429 1.4866 3.258 .0173  
(Year)^3: Δ9-THC 2.7165 1.2130 2.239 .0664  
Major_CVS~poly(Year, n=4)*Δ9-THC+CBDM+Tobacco+Opioids
Δ9-THC 0.5267 0.1820 2.894 .0178 0.4244 8.374 1,9 .01777
Majors2013~poly(Year, n=4)*Δ9-THC+CBDM+Tobacco+Opioids
(Year)^3: Δ9-THC 4.7555 1.0784 4.410 .0070 0.7843 9.179 4,5 .01592
(continued)
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Parameter Model
Parameter Estimate
Standard 
Error t Pr(>|t|) Adjusted R2 F df P
Year: Δ9-THC 3.3902 1.2164 2.787 .0386  
(Year)^2: Δ9-THC −3.6253 1.3525 −2.680 .0438  
Abbreviation: df, degrees of freedom.
Table 12. (continued)
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